BS2026

antibody from Bioworld Technology, Inc
Targeting: ADARB1 ADAR2, ADAR2a, ADAR2a-L1, ADAR2a-L2, ADAR2a-L3, ADAR2b, ADAR2c, ADAR2d, ADAR2g, DRABA2, DRADA2, hRED1, RED1
Provider product page for BS2026
Western blot
Immunohistochemistry

Antibody data

Product number
BS2026 - Provider product page
Provider
Bioworld Technology, Inc
Proper citation
Bioworld Technology Cat#BS2026, RRID:AB_1663215
Product name
ADAR2 (R510) polyclonal antibody
Antibody type
Polyclonal
Antigen
Synthetic peptide, corresponding to amino acids 480-530 of Human ADAR2.
Description
ADAR2, also designated adenosine deaminase, RNA-specific (RED1), RNA-editing enzyme 1, DRABA2, DRADA2, ADAR2Ï«-L1, ADAR2Ï«-L2 and ADAR2Ï«-L3, mediates RNA editing by destabilizing RNA through deamination of adenosine to inosine. ADAR2 is responsible for pre-mRNA editing of the glutamate receptor subunit B by site-specific deamination of adenosines. It can modify its own pre-mRNA and generate new splice sites. Translocation of endogenous ADAR2 from the nucleolus to the nucleoplasm results in increased editing of endogenous ADAR2 substrates. Alternative splicing of this gene results in several transcript variants that may influence RNA editing. RNA editing involves the deamination of adenosines at specific sites, the result of which can be a change in the amino acid sequence of the protein so that it differs from that predicted by the sequence of the DNA.
Reactivity
Human, Mouse, Rat
Host
Rabbit
Isotype
IgG
Vial size
100ul
Concentration
1 mg/ml
Storage
Store at 4°C short term. Aliquot and store at -20°C long term. Avoid freeze-thaw cycles.
ADARB1 protein structure - BS2026 shown in red.